newsfilter
← Latest News
Business Wire·

Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b "FORTRESS" Clinical Trial for Fibromyalgia

- Top line Data from the FORTRESS Study Expected in September 2022 - Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic disease